BioSpace News Archive

Takeda announced that it has entered into an exclusive licensing agreement with HUTCHMED Limited and its subsidiary HUTCHMED Limited, for the further development and commercialization of fruquintinib outside of mainland China, Hong Kong and Macau.

Alvotech announced the completion of a private placement of approximately $137 million, at current exchange rates, of its ordinary shares, par value $0.01 per share, at a purchase price of $11.57 per Share at current exchange rates.

MannKind Corporation today announced clofazimine inhalation suspension (MNKD 101) will advance to an adaptive Phase 2/3 study. Additionally, a paper has been published in the American Society for Microbiology journal.

Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF), an autologous stem cell therapy company, has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation.

A case study analysis of two patients has been presented by Regenative Labs (Regenative), a leading HCT/P manufacturer, in collaboration with Dr. Michael Lavor of Saguaro Surgical.

BiondVax Pharmaceuticals Ltd. today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug.

Asensus Surgical, Inc. today announced receipt of CE Mark for an expansion of machine vision capabilities on the previously cleared Intelligent Surgical Unit™ (ISU™).

Ra Medical Systems, Inc. (NYSE American: RMED) (Ra Medical), a medical device and technology company focused on cardiac electrophysiology, announces that four abstracts with clinical data supporting its VIVO technology have been accepted for presentation at the European Heart Rhythm Association Congress (EHRA 2023) being held April 16-18, 2023 in Barcelona.

Smart Immune SAS announced today that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial Sloan Kettering Cancer Center (MSK).

LAVA Therapeutics N.V. today announced that clinical data from a Phase 1/2a study in patients with therapy refractory metastatic castration resistant prostate cancer will be presented at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 16-18, 2023.